In May 2026, the AI-powered biotech pharmaceutical firm "Ark of Infinity" declared the successful closure of its seed funding round, raising tens of millions. This funding initiative was spearheaded by Monolith Capital. Established by Zhao Simiao, a doctoral candidate from Oxford, the company focuses on harnessing cross-species AI models to pioneer longevity medications and investigate treatments aimed at enhancing organ functionality.